JP2012508274A5 - - Google Patents

Download PDF

Info

Publication number
JP2012508274A5
JP2012508274A5 JP2011536383A JP2011536383A JP2012508274A5 JP 2012508274 A5 JP2012508274 A5 JP 2012508274A5 JP 2011536383 A JP2011536383 A JP 2011536383A JP 2011536383 A JP2011536383 A JP 2011536383A JP 2012508274 A5 JP2012508274 A5 JP 2012508274A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound according
independently
nitrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011536383A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012508274A (ja
JP5432275B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/063020 external-priority patent/WO2010056563A1/en
Publication of JP2012508274A publication Critical patent/JP2012508274A/ja
Publication of JP2012508274A5 publication Critical patent/JP2012508274A5/ja
Application granted granted Critical
Publication of JP5432275B2 publication Critical patent/JP5432275B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011536383A 2008-11-11 2009-11-03 Aktおよびp70s6キナーゼ阻害剤 Active JP5432275B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11327308P 2008-11-11 2008-11-11
US61/113,273 2008-11-11
PCT/US2009/063020 WO2010056563A1 (en) 2008-11-11 2009-11-03 Akt and p70 s6 kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2012508274A JP2012508274A (ja) 2012-04-05
JP2012508274A5 true JP2012508274A5 (enExample) 2012-07-12
JP5432275B2 JP5432275B2 (ja) 2014-03-05

Family

ID=41402451

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011536383A Active JP5432275B2 (ja) 2008-11-11 2009-11-03 Aktおよびp70s6キナーゼ阻害剤

Country Status (36)

Country Link
US (1) US8148387B2 (enExample)
EP (1) EP2358710B1 (enExample)
JP (1) JP5432275B2 (enExample)
KR (1) KR101334460B1 (enExample)
CN (1) CN102216302B (enExample)
AR (1) AR074072A1 (enExample)
AU (1) AU2009314324B2 (enExample)
BR (1) BRPI0921916A2 (enExample)
CA (1) CA2743019C (enExample)
CO (1) CO6382114A2 (enExample)
CR (1) CR20110240A (enExample)
CY (1) CY1113409T1 (enExample)
DK (1) DK2358710T3 (enExample)
DO (1) DOP2011000129A (enExample)
EA (1) EA018947B1 (enExample)
EC (1) ECSP11011048A (enExample)
ES (1) ES2391704T3 (enExample)
HN (1) HN2011001247A (enExample)
HR (1) HRP20120738T1 (enExample)
IL (1) IL211940A (enExample)
JO (1) JO2822B1 (enExample)
MA (1) MA32776B1 (enExample)
MX (1) MX2011005000A (enExample)
MY (1) MY161461A (enExample)
NZ (1) NZ592062A (enExample)
PA (1) PA8846901A1 (enExample)
PE (1) PE20110807A1 (enExample)
PL (1) PL2358710T3 (enExample)
PT (1) PT2358710E (enExample)
RS (1) RS52520B (enExample)
SI (1) SI2358710T1 (enExample)
TN (1) TN2011000207A1 (enExample)
TW (1) TWI422587B (enExample)
UA (1) UA100190C2 (enExample)
WO (1) WO2010056563A1 (enExample)
ZA (1) ZA201102549B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120640A1 (es) 2009-07-02 2012-06-09 Sanofi Sa Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida, su preparacion y su utilizacion farmaceutica como inhibidores de fosforilacion de akt (pkb)
BR112012011328A2 (pt) * 2009-10-23 2016-11-22 Lilly Co Eli inibidores de akt
MX336865B (es) 2011-04-07 2016-02-04 Bayer Pharma AG Imidazopiridazinas como inhibidores de quinasa akt.
ES2547687T3 (es) * 2011-07-09 2015-10-08 Xuanzhu Pharma Co., Ltd. Forma cristalina I de sal de un inhibidor de dipeptidil-peptidasa IV y procedimiento de preparación y uso de la misma
ES2646759T3 (es) 2011-09-12 2017-12-15 Merck Patent Gmbh Derivados de aminopirimidina para uso como moduladores de la actividad de la quinasa
HRP20171554T1 (hr) 2011-09-12 2017-11-17 Merck Patent Gmbh Novi imidazol amini kao modulatori aktivnosti kinaze
AR093512A1 (es) 2012-11-16 2015-06-10 Merck Patent Gmbh Derivados heterociclicos como moduladores de la actividad de cinasas
AR093511A1 (es) 2012-11-16 2015-06-10 Merck Patent Gmbh Derivados de imidazol-piperidinilo como moduladores de la actividad de cinasas
MX370448B (es) * 2013-03-11 2019-12-13 Merck Patent Gmbh Derivados de 6- [4- (1h-imidazol-2-il) piperidin-1-il] pirimidin-4-amina como moduladores de la actividad de cinasa.
JP6560243B2 (ja) * 2014-02-11 2019-08-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung キナーゼ活性のモジュレーターとしてのピリミジンイミダゾールアミン
TW201718574A (zh) 2015-08-12 2017-06-01 美國禮來大藥廠 Cgrp受體拮抗劑
JP6576553B2 (ja) * 2016-05-20 2019-09-18 大鵬薬品工業株式会社 新規5H−ピロロ[2,3−d]ピリミジン−6(7H)−オン誘導体
JP2023520140A (ja) * 2020-03-17 2023-05-16 江蘇恒瑞医薬股▲ふん▼有限公司 縮合二環系誘導体、その調製方法及びその医薬的応用
CN113444110B (zh) * 2020-03-25 2023-05-12 江苏恒瑞医药股份有限公司 四氢吡咯并吡唑类衍生物、其制备方法及其在医药上的应用
CA3231865A1 (en) 2021-09-17 2023-03-23 Tingting SHANG Fused bicyclic derivative, pharmaceutically acceptable salt, crystal form thereof and preparation method therefor
MA71401A (fr) * 2022-07-05 2025-04-30 Taiho Pharmaceutical Co., Ltd. 5h-pyrrolo[2,3-d]pyrimidine-6(7h)-one, et cristaux de sel de celui-ci

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
AU2005322085B2 (en) 2004-12-28 2012-07-19 Exelixis, Inc. [1H-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70S6K, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
US7423043B2 (en) * 2005-02-18 2008-09-09 Lexicon Pharmaceuticals, Inc. 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
US20090325924A1 (en) 2005-06-30 2009-12-31 Stuart Edward GPCR Agonists
WO2007125321A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
EP2037931A2 (en) 2006-04-25 2009-03-25 Astex Therapeutics Limited Pharmaceutical combinations of pk inhibitors and other active agents
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru) 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ

Similar Documents

Publication Publication Date Title
HRP20120738T1 (hr) Inhibitori kinaza akt i p70 s6
JP2007533741A5 (ja) Bace阻害剤として有用なピロリジン誘導体
JP2016516043A5 (enExample)
JP2011507849A5 (enExample)
NZ592297A (en) 2-Aryl-5-heteroaryl pyridine and pyrimidine derivatives as pharmaceutical active agents
JP2009516697A5 (enExample)
JP2018519323A5 (enExample)
JP2011512412A5 (enExample)
TNSN07164A1 (en) Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists
JP2008536825A5 (enExample)
NZ601794A (en) Di - substituted pyridine derivatives as anticancers
JP2015501799A5 (enExample)
JP2011513305A5 (enExample)
JP2014526549A5 (enExample)
JP2011502958A5 (enExample)
JP2008520742A5 (enExample)
JP2005510473A5 (enExample)
JP2012530765A5 (enExample)
JP2013530240A5 (enExample)
JP2013544276A5 (enExample)
JP2016513681A5 (enExample)
JP2017538773A5 (enExample)
JP2012507535A5 (enExample)
JP2016540811A5 (enExample)
JP2014510695A5 (enExample)